Transcription of The Stock Network Interview with LTR Pharma (ASX:LTP) Executive Chairman, Lee Rodney
Lel Smits: LTR Pharma is a biopharmaceutical business focused on improving men’s physical and mental health by bringing to market the first nasal spray used to treat erectile dysfunction, known as Spontan. Joining me to discuss more is LTR Pharma’s Executive Chairman, Lee Rodney. Lee, welcome to The Stock Network.
Lee Rodney: Thank you, it’s great to be here.
Lel Smits: Now, erectile dysfunction affects the quality of life for many men, making it a significant healthcare challenge around the world. Can you outline just how prevalent this condition is, and also how big the market opportunity you are targeting with your product Spontan?
Lee Rodney: Prevalence is very large. So it impacts 60% of men once you get to the age of 45 years or older. So that’s six out of 10 men after the age of 45 years of older. So it’s a very large market, multi-billion dollar blockbuster market that we’re entering.
Lel Smits: And looking at the product’s advantages over competitors, can you outline some of the drawbacks of existing treatments for erectile dysfunction, and also what advantages you believe your Spontan product presents?
Lee Rodney: Yeah, so it’s, these products are good light and standard treatments in the market are products called Viagra and Cialis. And Viagra really built this market. It’s a blockbuster market, multi-billion dollar market.
The main issues with those tablets is that you have to swallow them. So you have to, they have to go through your stomach and your digestive system before they’re effective. And that process takes up to an hour or longer.
And plus when you have food in your stomach, Viagra isn’t going to be very effective. So men really have to plan ahead with those, with those tablets. With our product as a nasal spray, we are the world’s first nasal spray product.
So our technology bypasses that digestive system, goes straight into the bloodstream, works within 10 minutes, and doesn’t have a food effect. So major, major advantages for our product Spontan. Okay.
Lel Smits: And Lee, finally, your commercialization push, you recently completed a $25 million capital raise to progress the commercialization of Spontan, both in Australia and the US. What deals do you already have in place to bring the product to market? And also what milestones can we look forward to this year? Yeah, we’re in a very strong position now after that $25 million raise.
Lee Rodney: So very, very strong cash balance. Last year, we’ve entered into a co-development agreement with, with Aptar Pharma. So Aptar is the world’s leader in nasal spray technologies. They’re US Nasdaq listed a $10 billion market cap.
So we’re very fortunate to have, to have done that partnership, that co-development partnership with Aptar. Recently in Australia, in the Australian market, we’ve done some commercial deals. So starting with our joint venture with a group called Restorative Sexual Health.
And they are experts in men’s health and erectile dysfunction. So men are able to now get online, get prescribed, have a consult with these experts right out of the privacy of their home. So we’re going to continue to grow those commercial opportunities here in the Australian market as we go through full regulatory approvals in the US and in the Australian market. So very exciting 12 months ahead with a lot of commercial news flow for us.
Lel Smits: Excellent. Great to hear those updates from LTR Pharma and we look forward to seeing you in person present to investors at Stocks on Track.
Lee Rodney: Looking forward to it.
Ends